Hims & Hers Health, Inc. (HIMS) Price Target Analysis
Updated Jun 18, 2026
Analyst Rating: Hold
Based on 20 analysts20.8% Above Target
HIMS trades 20.8% above Wall Street's consensus target of $28.08.
Current Price$35.47
Average Target$28.08
Target
Current
Low$12.50
Median$25.00
High$60.00
Analyst Target Range
Forward P/E—
PEG Ratio—
Implied Growth-59.3%
(Declining)
Analyst Spread169.2%
(Wide Disagreement)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes HIMS achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 20 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
HIMS Price Target Analysis
Updated June 21, 2026As of June 21, 2026, Hims & Hers Health, Inc. (HIMS) has a Wall Street consensus price target of $28.08, based on estimates from 20 covering analysts. With the stock currently trading at $35.47, this represents a potential downside of -20.8%. The company has a market capitalization of $7.79B.
Analyst price targets range from a low of $12.50 to a high of $60.00, representing a 169% spread in expectations. The median target of $25.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Hold, with 7 analysts rating the stock as a Buy or Strong Buy,13 rating it Hold, and 0 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, HIMS trades at a trailing P/E of 69.5x. Analysts expect EPS to grow -59.3% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $6.33, with bear and bull scenarios of $3.99 and $8.33 respectively. Model confidence stands at 59/100, reflecting moderate uncertainty in projections.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+33.3%
Industry Consensus
Avg Forward P/E
26.9x
(Growth Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 TDOCTeladoc Health, Inc. | $1.5B | $8.07 | $7.40 | -8.3% | Hold | — | 42 |
 DOCSDoximity, Inc. | $3.8B | $20.46 | $29.47 | +44.0% | Hold | 14.3x | 23 |
 OPRXOptimizeRx Corporation | $93M | $4.98 | $17.00 | +241.4% | Buy | 5.3x | 15 |
 WELLWelltower Inc. | $144.8B | $206.65 | $237.80 | +15.1% | Buy | 71.3x | 34 |
 NVONovo Nordisk A/S | $191.9B | $43.19 | $45.00 | +4.2% | Buy | 2.0x | 39 |
 LLYEli Lilly and Company | $1.0T | $1098.13 | $1271.24 | +15.8% | Buy | 30.0x | 45 |
 AMWLAmerican Well Corporation | $141M | $8.43 | $6.33 | -24.9% | Hold | — | 15 |
 TALKTalkspace, Inc. | $873M | $5.21 | $5.25 | +0.8% | Hold | 38.6x | 10 |
 GDRXGoodRx Holdings, Inc. | $922M | $2.66 | $3.08 | +15.8% | Hold | 8.6x | 24 |
 HCATHealth Catalyst, Inc. | $129M | $1.74 | $2.25 | +29.3% | Buy | 44.8x | 22 |
HIMS — Frequently Asked Questions
Quick answers to the most common questions about buying HIMS stock.
What is the HIMS stock price target for 2026?
HIMS's consensus price target is $28.08, -20.8% below the current price of $35.47. The 20 analysts tracking HIMS see downside risk at present valuations.
Is HIMS a buy, sell, or hold?
HIMS has a consensus rating of "Hold" based on 20 Wall Street analysts. The rating breakdown is mixed, with 13 Hold ratings making up the largest segment. The consensus 12-month price target of $28.08 implies -20.8% downside from current levels.
Is HIMS stock overvalued or undervalued?
HIMS's current price is $35.47 with a consensus target of $28.08 (-20.8% implied move). Analyst estimates suggest the stock is overvalued at current levels.
How high can HIMS stock go?
The most bullish Wall Street analyst has a price target of $60 for HIMS, while the most conservative target is $12.5. The consensus of $28.08 represents the median expectation. Our quantitative valuation model projects a bull case target of $8 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover HIMS stock?
HIMS is well covered by analysts, with 20 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 7 have Buy ratings, 13 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the HIMS stock forecast?
The 12-month HIMS stock forecast based on 20 Wall Street analysts shows a consensus price target of $28.08, with estimates ranging from $12.5 (bear case) to $60 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $6, with bear/bull scenarios of $4/$8.
What is HIMS's fair value based on fundamentals?
Our quantitative valuation model calculates HIMS's fair value at $6 (base case), with a bear case of $4 and bull case of $8. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 59/100.
Should I buy HIMS stock?
Analysts are cautious on HIMS, with 0 Sell ratings and a price target of $28.08 (-20.8% from current price). The "Hold" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do HIMS price targets vary so much?
HIMS analyst price targets range from $12.5 to $60, a 169% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $28.08 consensus represents the middle ground. Our model's $4-$8 range provides an independent fundamental perspective.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare